<DOC>
	<DOCNO>NCT01946906</DOCNO>
	<brief_summary>Patients Common variable immunodeficiency ( CVID ) various form autoimmune auto inflammatory disorder . The study investigate intervention Rifaximin modify gut microbiota subsequent alteration marker systemic immune activation inflammation patient CVID . The investigator hypothesize gut microbiota CVID patient , least partly interaction innate immune system within intestine , contribute low-grade systemic inflammation patient , intervention non-absorbable antibiotic Rifaximin attenuate systemic inflammation modulation gut microbiota . The study may lead increase understanding interaction microbiota immune system . The study could give new insight important disease process relation interaction microbiota , intestine systemic compartment , potentially basis new therapeutic strategy patient prevent down-regulate auto-inflammatory autoimmune complication see CVID . The finding could also relevance disorder interaction microbiota intestinal systemic inflammation involve various cardiovascular metabolic disorder . The investigator hypothesize gut microbiota CVID patient , least partly interaction innate immune system within intestine , contribute low-grade systemic inflammation patient , intervention non-absorbable antibiotic Rifaximin attenuate systemic inflammation modulation gut microbiota .</brief_summary>
	<brief_title>The Rifaximin Study CVID</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>18 â‰¥ &lt; 75 year age A diagnosis CVID : decrease serum level ( &gt; 2 SD ) immunoglobulin ( Ig ) G , IgA and/or IgM exclusion form hypogammaglobulinemia Previous treatment antibiotic within last 12 week History hypersensitivity Rifaximin Rifamycin derive antimicrobial agent , component XIFAXAN Comorbidity relate CVID i.e . condition symptom may influence patient safety compromise study result ( e.g. , cardiovascular disorder , alcoholism , psychiatric disease , HIV infection etc. ) ] . Polypharmacy increase risk interaction . i.e . patient extensive medication list ( e.g . 10 drug ) may influence patient safety compromise study result Malignancy cause Impaired kidney function ( i.e. , estimate glomerulus filtration rate &lt; 50 ml/minute/1.73 m2 ] Impaired liver function ( Alanine aminotransferase &gt; 150 U/l ) establish liver cirrhosis . Pregnant planning pregnant study period avoid interference pregnancy gut microbiota ( toxicity ] . Nursing Ongoing infection , include GI infection The use probiotic recent 6 month Any immunosuppressive drug ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>